<DOC>
	<DOCNO>NCT00567398</DOCNO>
	<brief_summary>Primary Objective : To demonstrate use glucose spar prescription ( PEN v Dianeal ) diabetic ( Type 1 Type 2 ) Continuous Ambulatory Peritoneal Dialysis ( CAPD ) Automated Peritoneal Dialysis ( APD ) patient lead improved metabolic control measure magnitude change baseline value HbA1c level . Secondary Objectives : To demonstrate use glucose-sparing PD solution ( PEN v Dianeal ) diabetic ( Type 1 Type 2 ) CAPD APD patient lead low glycemic-control medication requirement , decrease incidence severe hypoglycemic event require medical intervention , improve metabolic control , nutritional status , Quality Life . In subgroup patient , impact glucose-sparing PD solution ( PEN v Dianeal ) abdominal fat leave ventricular ( LV ) structure function assess .</brief_summary>
	<brief_title>IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD APD Patients</brief_title>
	<detailed_description />
	<mesh_term>Icodextrin</mesh_term>
	<criteria>1 . M/F patient 18 year age old 2 . Diagnosis ESRD ( GFR ≤ 15 mL/min ) 3 . CAPD APD use Dianeal and/or Physioneal , least 1 exchange 2.5 % 4.25 % dextrose/day , prescribe dry time 4 . DM ( Type 1 2 ) glycemiccontrol medication , 90 day 5 . HbA1c &gt; 6.0 % ≤ 12.0 % 6 . Blood hemoglobin ≥ 8.0 g/dL , ≤ 13.0 g/dL 1 . Cardiovascular event within last 90 day 2 . Ongoing clinically significant congestive heart failure ( NYHA class III IV ) 3 . Allergy starchbased polymer 4 . Glycogen storage disease 5 . Glycogen storage disease 6 . Peritonitis , exitsite tunnel infection treat antibiotic within last 30 day 7 . Mean Arterial Pressure ( MAP ) ≥ 125 mm Hg , volume deplete ( MAP &lt; 77 ) Screening . 8 . Serum urea &gt; 30 mmol/L 9 . Receiving rosiglitazone maleate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>ESRD</keyword>
	<keyword>Diabetes</keyword>
	<keyword>CAPD</keyword>
	<keyword>APD</keyword>
</DOC>